1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone.
(
- Contribution to journal › Article
- 2010
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
- 2008
-
Mark
Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.524-525(
- Contribution to journal › Published meeting abstract
- 2002
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article